LifeMap Sciences Adds Products Through Partnership with ProSpec-Tany
- BioTime Subsidiary offers 100 select recombinant proteins in its BioReagents
ALAMEDA, Calif. -- April 10, 2013
LifeMap Sciences, Inc., a subsidiary of BioTime, Inc. (NYSE MKT: BTX),
announced today that it is now offering 100 selected ProSpec-Tany TechnoGene
(ProSpec) manufactured recombinant proteins related to stem cell research in
its recently launched LifeMap BioReagents™ portal
(http://bioreagents.lifemapsc.com) to researchers worldwide. ProSpec’s
innovative recombinant proteins, including growth factors, signaling
molecules, differentiation factors, hormones, cytokines and chemokines will
complement the current BioTime research product lines available via LifeMap
BioReagents™, including BioTime’s PureStem™ human progenitor cell lines,
PureStem™ packages, clinical and research grade human embryonic stem cell
lines (hES), ESpan™ growth media for progenitor cell lines, and cell
The addition of ProSpec products reflects LifeMap Sciences’ execution of its
strategy to market a growing catalog of research products to aid scientists in
a variety of fields, including stem cell research, developmental biology,
mechanisms of various human diseases and drug and therapeutic discovery.
LifeMap Sciences holds an exclusive, worldwide license to market GeneCards^®
(www.genecards.org), the human gene compendium, and MalaCards
(www.malacards.org), a database with nearly 17,000 human disease entries, from
Yeda Research and Development Company Ltd., the commercial arm of the Weizmann
Institute of Science. Additionally, it has recently launched version 1.1 of
LifeMap Discovery™, a comprehensive embryonic development and stem cell
compendium, a database owned and developed by LifeMap Sciences. According to
Google Analytics, the sites have generated more than 2,000,000 unique visitors
with more than 13,000,000 page views in the past 12 months. Links from LifeMap
Discovery™ to BioTime and ProSpec manufactured products in the LifeMap
BioReagents™ portal will enable researchers who access the database to become
familiar with, and purchase, products that relate directly to the types of
cells, genes or diseases that they are studying and can assist them in various
“We are pleased to meet this significant milestone in our e-Commerce
strategy,” stated Yaron Guan-Golan, Head of Marketing at LifeMap Sciences.
“Our growing LifeMap Discovery™ user base will now be able to identify high
quality recombinant proteins that can be helpful for their research and
purchase them via LifeMap BioReagents™. This will increase LifeMap
BioReagents™ brand awareness and the quality of our offering to the global
biomedical research community.”
About LifeMap Sciences, Inc.
LifeMap Sciences’ (www.lifemapsc.com) core technology and business is based on
its integrated database suite, the discovery platform for biomedical and stem
cell research. This platform includes GeneCards^®, the leading human gene
database; LifeMap Discovery™, the database of embryonic development, stem cell
research and regenerative medicine; and MalaCards, the human disease database.
LifeMap Sciences also markets PanDaTox, an innovative, recently developed,
searchable database that can aid in the discovery of new antibiotics and
biotechnologically beneficial products.
In addition to database offerings, LifeMap Sciences is BioTime’s principal
marketing subsidiary for research products, including PureStem™ human
progenitor cell lines, GMP human embryonic stem (hES) cell lines, ESpan™
growth media for progenitor cell lines, and cell differentiation media for
non-therapeutic uses, via its LifeMap BioReagents™ portal. LifeMap Sciences
utilizes its databases as part of its online marketing strategy to reach life
sciences researchers at biotech and pharmaceutical companies and at academic
institutions and research hospitals worldwide.
In a therapeutic discovery collaboration with BioTime, LifeMap’s scientists
utilize LifeMap’s proprietary platform, including LifeMap Discovery™, its stem
cell database along with the GeneCards^® and MalaCards integrated database
suite, to aid in the development of BioTime’s proprietary PureStem™ human
progenitor cell lines into products for the treatment of human diseases,
especially degenerative diseases that might be treatable with cell replacement
therapies. The LifeMap Discovery™ platform will be used to select the
progenitor cell lines that are most likely to be useful in developing
cell-based regenerative medicine therapies for a wide range of diseases.
About ProSpec-Tany TechnoGene Ltd.
ProSpec (Protein-Specialists) is a leading biotechnology company having over
19 years of experience specializing in production of bacterial-derived
recombinant proteins. ProSpec produces a wide array of Cytokines, Growth
Factors, Chemokines, Hormones, Enzymes, Viral Antigens and many other
ProSpec’s proprietary protein purification technologies with over a decade of
extensive experience result in low production costs, high yield, production
efficiency, utmost pure products and uncompromising biological activity at
competitive prices. ProSpec provides custom in-house production services of
recombinant proteins tailored to the customer's needs.
ProSpec provides proteins, services and technologylicense to a broad range of
customers around the globefrom academic and government research
institutions,biotechnology and pharmaceutical companies, as well as hospitals
and reference laboratories.
ProSpec's goal is to supply proteins which are crucial to the research
industry to meet and exceed quality, consistency and requirements by our
customers worldwide. The company welcomes partnerships with pharmaceutical and
industrial companies for development of future proteins.
About BioTime, Inc.
BioTime, headquartered in Alameda, California, is a biotechnology company
focused on regenerative medicine and blood plasma volume expanders. Its broad
platform of stem cell technologies is enhanced through subsidiaries focused on
specific fields of application. BioTime develops and markets research products
in the fields of stem cells and regenerative medicine, including a wide array
of proprietary PureStem™ cell lines, HyStem^® hydrogels, culture media, and
differentiation kits. BioTime is developing Renevia™ (formerly known as
HyStem^®-Rx), a biocompatible, implantable hyaluronan and collagen-based
matrix for cell delivery in human clinical applications. BioTime's therapeutic
product development strategy is pursued through subsidiaries that focus on
specific organ systems and related diseases for which there is a high unmet
medical need. BioTime's majority owned subsidiary Cell Cure Neurosciences Ltd.
is developing therapeutic products derived from stem cells for the treatment
of retinal and neural degenerative diseases. BioTime's subsidiary OrthoCyte
Corporation is developing therapeutic applications of stem cells to treat
orthopedic diseases and injuries. Another subsidiary, OncoCyte Corporation,
focuses on the diagnostic and therapeutic applications of stem cell technology
in cancer, including the diagnostic product PanC-Dx™ currently being developed
for the detection of cancer in blood samples. ReCyte Therapeutics, Inc. is
developing applications of BioTime's proprietary induced pluripotent stem cell
technology to reverse the developmental aging of human cells to treat
cardiovascular and blood cell diseases. BioTime's subsidiary LifeMap Sciences,
Inc. markets GeneCards^®, the leading human gene database, as part of an
integrated database suite that also includes the LifeMap Discovery™ database
of embryonic development, stem cell research and regenerative medicine, and
MalaCards, the human disease database. LifeMap Sciences also markets BioTime
research products and PanDaTox, an innovative, recently developed, searchable
database that can aid in the discovery of new antibiotics and
biotechnologically beneficial products. Asterias Biotherapeutics, Inc. is a
new subsidiary being used to acquire the stem cell assets of Geron
Corporation, including patents and other intellectual property, biological
materials, reagents and equipment for the development of new therapeutic
products for regenerative medicine. BioTime's lead product, Hextend^®, is a
blood plasma volume expander manufactured and distributed in the U.S. by
Hospira, Inc. and in South Korea by CJ CheilJedang Corporation under exclusive
licensing agreements. Additional information about BioTime can be found on the
web at www.biotimeinc.com.
Statements pertaining to future financial and/or operating results, future
growth in research, technology, clinical development, and potential
opportunities for BioTime and its subsidiaries, along with other statements
about the future expectations, beliefs, goals, plans, or prospects expressed
by management constitute forward-looking statements. Any statements that are
not historical fact (including, but not limited to statements that contain
words such as "will," "believes," "plans," "anticipates," "expects,"
"estimates") should also be considered to be forward-looking statements.
Forward-looking statements involve risks and uncertainties, including, without
limitation, risks inherent in the development and/or commercialization of
potential products, uncertainty in the results of clinical trials or
regulatory approvals, need and ability to obtain future capital, and
maintenance of intellectual property rights. Actual results may differ
materially from the results anticipated in these forward-looking statements
and as such should be evaluated together with the many uncertainties that
affect the business of BioTime and its subsidiaries, particularly those
mentioned in the cautionary statements found in BioTime's Securities and
Exchange Commission filings. BioTime disclaims any intent or obligation to
update these forward-looking statements.
To receive ongoing BioTime corporate communications, please click on the
following link to join our email alert list:
Chief Financial Officer
510-521-3390, ext 367
510-521-3390, ext 301
LifeMap Sciences, Inc.
Press spacebar to pause and continue. Press esc to stop.